{
  "pmcid": "3646287",
  "sha256": "b9391e224347f2b46d7e6d3a09b442339941c75b9f8b96bbeea7fb4906b85411",
  "timestamp_utc": "2025-11-09T22:37:52.156585+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.449122807017542,
    "reading_ease": 35.538859649122855,
    "word_count": 228
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Fetal Striatal Transplantation in Huntington's Disease"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial involved 17 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "17 patients with mild HD from the NEST-UK cohort"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Five patients were randomly selected for bilateral fetal striatal transplantation, while 12 served as controls"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the safety and efficacy of fetal striatal transplantation in HD"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in the Unified Huntington's Disease Rating Scale (UHDRS) motor score over 10 years"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence, and allocation was concealed"
      },
      "Blinding": {
        "score": 0,
        "evidence": "The study was open-label, with no blinding of patients or clinicians"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between 2000 and 2003, five patients received transplants"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "No significant differences were observed in UHDRS scores between the transplant and control groups over 10 years"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The mean difference in UHDRS motor score was not significant (p > 0.05)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included transient renal function decline and anaemia, resolving after immunosuppression cessation"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ISRCTN36485475"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by the NEST-UK consortium"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}